Cancer News

FDA grants breakthrough therapy designation to Keytruda-Lenvima combination for hepatocellular carcinoma (07/24/2019)

The FDA granted breakthrough therapy designation to pembrolizumab in combination with lenvatinib as first-line treatment for patients with advanced unresectable hepatocellular carcinoma who are not able to receive locoregional treatment. This is the third breakthrough therapy designation granted by FDA for pembrolizumab (Keytruda, Merck) — an anti-PD-1 therapy — and lenvatinib (Lenvima, Eisai), a multiple... Continue Reading

Keytruda Immunotherapy for Treatment of Liver Cancer (11/13/2018)

According to the results of a study presented at the recent gastrointestinal cancer symposia, Keytruda (pembrolizumab) is an active treatment for advanced liver cancer in patients who have already been treated with Nexavar (sorafenib), (1) and has not been approved by the US for use in patients with liver cancer. Keytruda was approved as a …

Continue reading "Keytruda Immunotherapy for Treatment of Liver Cancer"

FDA Approves Lenvatinib for Treatment of Advanced Hepatocellular Cancer (08/20/2018)

The U.S. Food and Drug Administration (FDA) approved the kinase inhibitor LENVIMA® (lenvatinib) for the first-line treatment of patients with unresectable hepatocellular carcinoma (HCC). This approval was based on results from REFLECT, where LENVIMA demonstrated a proven treatment effect on overall survival as well as statistically significant superiority and clinically meaningful improvements in progression-free survival …

Continue reading "FDA Approves Lenvatinib for Treatment of Advanced Hepatocellular Cancer"

Cyramza Improves Survival in Poor-Prognosis Liver Cancer (07/12/2018)

Andrew X. Zhu, MD, PhD, director of Liver Cancer Research at Massachusetts General Hospital presented new data at the 2018 World Congress on Gastrointestinal Cancer (WCGC) demonstrating that Cyramza (ramucirumab) significantly improves survival in a subset of patients with hepatocellular carcinoma (HCC) who have high levels of the plasma protein α-fetoprotein (AFP), which is associated …

Continue reading "Cyramza Improves Survival in Poor-Prognosis Liver Cancer"

Cabometyx™ May Be ‘New Treatment Option’ for Liver Cancer (02/20/2018)

CancerConnect News:  Treatment with Cabometyx™  (cabozantinib) significantly improved outcomes in patients with advanced hepatocellular carcinoma (HCC), leading researchers to suggest that it could offer a new treatment option for this patient population.  The new findings come from the phase 3 CELESTIAL trial and were presented at the 2018 Gastrointestinal Cancers Symposium.1 About Liver Cancer Liver …

Continue reading "Cabometyx™ May Be ‘New Treatment Option’ for Liver Cancer"

Keytruda Immunotherapy Appears Active for Treatment of Liver Cancer (02/15/2018)

CancerConnect News:  According to the results of a study presented at the recent gastrointestinal cancer symposia, Keytruda (pembrolizumab) is an active treatment for advanced liver cancer in patients who have already been treated with Nexavar (sorafenib).1 About Liver Cancer Liver cancer, or hepatocellular carcinoma (HCC), is the second most common cause of cancer-related deaths worldwide.2,3 …

Continue reading "Keytruda Immunotherapy Appears Active for Treatment of Liver Cancer"

Opdivo Precision Cancer Medicine Improves Outcomes in Advanced Liver Cancer (05/18/2017)

Results from the CheckMate 040 clinical trial have been recently reported and found that Opdivo (nivolumab), an immuno-oncology drug which acts by modulating the immune system, produces durable responses with long-term survival rates in patients with liver cancer, regardless of whether or not patients were infected with Hepatitis B or C.  These study results were …

Continue reading "Opdivo Precision Cancer Medicine Improves Outcomes in Advanced Liver Cancer"

First New Drug for Liver Cancer in a Decade: Stivarga (05/08/2017)

The US Food and Drug Administration (FDA) has expanded the indication for Stivarga (regorafenib) to now include treatment for patients with hepatocellular carcinoma (HCC) who have previously been treated with the drug Nexavar. Expansion of Stivarga, ‘s indication marks the first FDA-approved treatment for a liver cancer in almost a decade. Stivarga is an oral …

Continue reading "First New Drug for Liver Cancer in a Decade: Stivarga"

Vistogard® Approved for Life-Threatening Toxicities of Certain Chemotherapy Agents (02/11/2016)

The United States Food and Drug Administration (FDA) approved Vistogard (uridine triacetate) for the treatment of life-threatening toxicities caused by the chemotherapy drugs fluorouracil or capecitabine. The approved indication is for the “emergency treatment of adults and children who receive an overdose of the cancer treatment fluorouracil or Xeloda (capecitabine), or who develop certain severe … Continue reading "Vistogard® Approved for Life-Threatening Toxicities of Certain Chemotherapy Agents"